Why Is AdaptHealth Corp. (AHCO) Stock Down -38.04% Today?
Key Takeaways
- AdaptHealth Corp. shares plummeted 38.04% to close at $6.71, one of the steepest single-day declines in the company's history.
- The selloff was triggered by a disastrous Q2 2026 earnings report that missed Wall Street expectations across nearly every metric.
- The company reported a loss of $0.99 per share versus consensus estimates for a $0.15 profit, and revenue of $740.3 million missed the $848.9 million forecast.
- Full-year guidance was slashed dramatically, with the revenue midpoint dropping to $2.87 billion from the prior $3.49 billion consensus, and adjusted EBITDA guidance cut by roughly $175 million.
- A $144.2 million goodwill impairment charge, West Coast capitated contract headwinds, and a surprise manufacturer price increase all contributed to the massive earnings reset.
- Trading volume surged to approximately 19 million shares, more than 13 times the average daily volume, signaling a broad repricing of the stock by institutional and retail investors alike.
Opening Summary
AHCO, AdaptHealth Corp. — a leading provider of home medical equipment, supplies, and related services to patients with chronic conditions — saw its stock collapse 38.04% on Tuesday, closing at $6.71 after opening at just $6.68. The prior session closed at $10.83. The catastrophic decline followed the release of second-quarter 2026 earnings that fell dramatically short of analyst expectations and included a severe reduction in full-year financial guidance. The home medical equipment distributor, which operates approximately 680 locations across all 50 states, now trades near the bottom of its 52-week range of $6.14 to $13.43.
Q2 Earnings: A Miss of Historic Proportions
The primary catalyst behind AHCO's collapse was an earnings report that missed almost every consensus estimate. AdaptHealth reported an adjusted loss of $0.99 per share, compared to analyst expectations of a $0.15 profit — a miss of $1.14 per share. Revenue came in at $740.3 million, well below the $848.9 million consensus, despite representing 12.7% year-over-year growth from $657.1 million in the prior-year quarter.
While the company touted 15.9% organic revenue growth across all business segments — its highest quarterly rate in over a year — the bottom line told a far more troubling story. Net loss reached $145.3 million, compared with net income of $4.2 million in Q2 2025, driven largely by a $144.2 million non-cash goodwill impairment charge across the Respiratory Health and Wellness at Home reporting units. Adjusted EBITDA declined 3.2% year-over-year to $132.0 million, with margins compressing to 17.8% from 20.8% a year earlier.
Guidance Slashed Across the Board
Perhaps even more damaging than the quarterly miss was the company's dramatic reset of full-year expectations. AdaptHealth cut its fiscal 2026 revenue guidance to a range of $2.85 billion to $2.89 billion, with a midpoint of $2.87 billion — roughly 17.6% below the Wall Street consensus of approximately $3.49 billion. Adjusted EBITDA guidance was lowered to $490 million to $520 million, down from prior expectations of $680 million to $730 million. Free cash flow guidance was slashed to a range of $80 million to $120 million.
CEO Suzanne Foster acknowledged on the earnings call that the complexity of the company's transition toward capitated revenue models had "impacted margins," despite what she described as "record volume gains across the business." The guidance reset reflected a confluence of headwinds: a $55 million impact from operational challenges with a West Coast capitated contract, a $30 million hit from a surprise manufacturer price increase, $15 million tied to portfolio rationalization actions, and a $100 million impact from the Diabetes Health divestiture — including $60 million in stranded corporate overhead.
West Coast Contract and Manufacturer Shock
A significant portion of the profitability pressure stemmed from AdaptHealth's large capitated contract on the West Coast, which missed internal expectations by approximately $15 million in the second quarter alone. Management estimated the contract would generate a $40 million profitability headwind in the second half of the year, citing higher-than-expected sleep resupply volumes, enteral demand, and elevated labor and logistics costs. The company expects only gradual improvement, targeting a 20% margin on capitated agreements by next year.
Compounding the challenges, a large unnamed manufacturer terminated its contract and imposed an immediate price increase, creating a $30 million second-half impact that the company had no prior visibility into. Foster described the development as "unusual and unfortunate," noting that mid-year price increases cannot be passed through to payers, forcing AdaptHealth to explore supplier mix changes and product profitability optimization as offsetting measures.
Market Context and Trading Activity
The trading volume for AHCO on Tuesday reached roughly 19 million shares, a staggering surge compared to the average daily volume of approximately 1.4 million shares. The stock opened at $6.68 — a gap down of roughly 38% from Friday's close — and traded within a range of $6.14 to $7.03, touching its 52-week low intraday. The move far exceeded the typical post-earnings reaction for the stock, indicating that the magnitude of the earnings reset caught the market off guard and triggered a wholesale repricing of the company's equity.
The selloff in AHCO was company-specific rather than sector-driven. Broader healthcare and home medical equipment peers did not exhibit similar moves, and the major indices were not materially correlated with the decline. The stock is now down roughly 32% year-to-date and trading more than 51% below its 52-week high of $13.43 reached in April 2026.
What Comes Next for AHCO
Investors will now focus intensely on AdaptHealth's ability to execute against its reset guidance and stabilize margins. The planned $235 million sale of its Diabetes Health business, announced after quarter-end, is designed to streamline the portfolio and pay down debt — management is targeting net leverage of 2.5 times. Additionally, a restructuring program expected to deliver $19 million in annualized savings signals a commitment to cost discipline.
Key risks include the unresolved manufacturer contract dispute, ongoing West Coast contract ramp-up challenges, the absorption of stranded corporate overhead from the Diabetes divestiture, and execution risk around the company's strategic pivot toward capitated revenue models. A securities investigation announced by Holzer & Holzer adds a layer of legal uncertainty. Upcoming third-quarter results will serve as a critical checkpoint for whether management's turnaround narrative is gaining traction or whether deeper structural issues persist. Analysts, who had maintained a consensus price target well above current levels, are likely to issue significant downward revisions in the days ahead.
Trending AI Robots
For traders seeking to navigate volatile market environments like the one that engulfed AdaptHealth, Tickeron offers a curated selection of AI-powered trading bots at its Trending AI Robots page. Hundreds of AI trading bots cover thousands of tickers, but only the strongest performers under current market conditions are featured in this dynamic, curated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to find approaches matched to their own risk tolerance and investment style. Explore the Trending AI Robots page to discover which algorithms are currently navigating market conditions most effectively.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
AHCO sees its Stochastic Oscillator ascends from oversold territory
On October 01, 2026, the Stochastic Oscillator for AHCO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In 53 of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in 226 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 132 of 184 cases where AHCO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AHCO as a result. In 70 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AHCO broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.547) is normal, around the industry mean (10.853). P/E Ratio (16.491) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.240) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. AHCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices
Advertisement